Conference Reports for NATAP

Back

The International Liver Congress™ EASL - European Association for the Study of the Liver Barcelona, Spain 13-17 April 2016     Summary from EASL 2016 for Hepatitis C Highly efficacious pan-genotypic DAA combinations on their way: the last gaps in difficult-to-treat patient populations are going to be closed soon. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany Correspondence: Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany - (06/01/16)   FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE MODEL OF NASH - (12/02/16)   RG-101 DEMONSTRATES FAVORABLE IN VITRO ANTIVIRAL ACTIVITY AND CROSS RESISTANCE PROFILE TO SUPPORT CLINICAL COMBINATION STUDIES IN HCV PATIENTS - (12/02/16)   HCV DAAs Resistance / New HCV Drugs - Direct antiviral combination treatment according to presence of baseline RAVs in NS3, NS5A and NS5B leads to high SVR rates in non-cirrhotic and cirrhotic genotype 1 infected patients - (05/31/16)   A NOVEL TASK SHIFTING MODEL TO EXPAND THE HCV CARE CONTINUUM: THE ASCEND INVESTIGATION - (05/31/16)   EFFECTIVENESS AND SAFETY OF DAA COMBINATION THERAPIES FOR TREATMENT OF HCV IN ELDERLY PATIENTS (>70 YRS.): RESULTS FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R) - (05/31/16)   Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study - (05/27/16)   Retreatment of Patients who failed DAA-Combination Therapies: Real-World Experience from a Large Hepatitis C Resistance Database - (05/27/16)   Daclatasvir+SOF at EASL 2016 - (05/18/16)   Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Renal Impairment - (05/18/16)   Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Hepatic Impairment - (05/10/16)   ABT-493 AND ABT-530 COMBINATION DEMONSTRATED MINIMAL POTENTIAL FOR CYP-MEDIATED DRUG-DRUG INTERACTIONS - (05/10/16)   Sustained Virologic Response Predicts Fibrosis Regression Measured by FibroTest in HCV-Infected Patients - 'Earliest Treatment Provides Most Regression' *** - (05/09/16)   Reductions in Lifetime Risks of Liver-Related Morbidity and Mortality Associated with Novel Direct-Acting Antiviral Regimens Recommended for Treating Genotype 4 Non-Cirrhotic Hepatitis C Patients in the United States - (05/09/16)   Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-I) - (05/09/16)   HIV Coinfection Impairs the Response to DAA-based HCV Therapy - (05/09/16)   Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-I) - (05/09/16)   HIV Coinfection Impairs the Response to DAA-based HCV Therapy - (05/09/16)   DAA-induced HCV clearance does not restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.... from Jules: is HCC recurrence associated with lack of benefit associated with Interferon-based therapy? and cytokine response? - (05/09/16)   Decreasing incidence of cancer after liver transplantation - A Nordic population-based study - (05/09/16)   CPI-431-32, A Novel Cyclophilin Inhibitor for Treatment of Chronic Hepatitis B: A Story of Clinical Utility - (05/03/16)   Combination Therapy for Curing HBV - Arbutus BioPharma - (05/03/16)   In Vitro and In Vivo Antiviral Activities of AB-423 a Potent Small Molecule Inhibitor of Hepatitis B Virus Capsid Assembly - (05/03/16)   The effect of sofosbuvir containing regimens in patients with HCV genotype 3 - A Scandinavian real-life experience. [effect of cirrhosis/CP-A/B/C - (05/03/16)   The presence of diabetes mellitus is a strong risk factor for hepatocellular carcinoma in hepatitis C infected patients with advanced fibrosis or cirrhosis who have achieved sustained virological response. - (05/03/16)   PREVALENCE AND CLINICAL IMPORTANCE OF HEPATITIS C VIRUS GENOTYPE 2K/1B CHIMERAS - (05/03/16)   EFFECTIVENESS AND SAFETY OF OMBITASVIR, PARITAPREVIR, RITONAVIR AND DASABUVIR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS FROM THE SPANISH REAL WORLD COHORT - (05/03/16)   ABT-493 + ABT-530 at EASL - (05/03/16)   Sofosbuvir / Velpatasvir.... + GS-9857 - (05/03/16)   Newest HCV Drugs at EASL - (05/03/16)   Analysis of HCV Genotype 2 and 3 Variants in Patients Treated With Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530 - (05/03/16)   Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin, in adults treated with the regimen approved in Australia, Canada, New Zealand and Switzerland .....Global Cohorts/ABT493+ABT530 - (05/03/16)   Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir Without Ribavirin in Patients with HCV Genotype 1b With or Without Compensated Cirrhosis: Pooled Analysis Across 5 Clinical Trials - (05/03/16)   Sustained Virologic Response to Daclatasvir and Sofosbuvir, With or Without Ribavirin, Among Patients in the French Daclatasvir ATU programme Infected With HCV Genotypes 4, 5 and 6 - (05/02/16)   Effectiveness of Daclatasvir-Based Therapy in Patients With Chronic Hepatitis C in Europe: Experience From the Named Patient Program - (05/02/16)   Factors Impacting SVR12 for Patients With Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir With Ribavirin in the ALLY-1 Study - (05/02/16)   Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir in HCV-Infected Subjects With Advanced Liver Disease and/or Following Liver Transplantation - (05/02/16)   Ledipasvir/Sofosbuvir With Ribavirin for 12 Weeks Is Effective and Safe in Treatment-Naïve Genotype 3 HCV-Infected Patients in Canada - (05/02/16)   On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome During Therapy With Ledipasvir/Sofosbuvir With or Without Ribavirin in the Phase 3 ION-1 Study - (04/29/16)   An Integrated Safety and Efficacy Analysis of Sofosbuvir-Based Regimens in Patients With Hereditary Bleeding Disorders - (04/29/16)   Final SVR24 Data from the Phase 3 C-EDGE Treatment-Naïve Study of Elbasvir/Grazoprevir in Patients With Chronic HCV Genotype 1, 4, or 6 Infection - (04/29/16)   EUROPEAN RAVS DATABASE: FREQUENCY AND CHARACTERISTICS OF RAVS IN TREATMENT-NAïVE AND DAA-EXPERIENCED PATIENTS - (04/29/16)   OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY: THE QUARTZ-I STUDY....95-100% SVR - (04/29/16)   C-SWIFT RETREATMENT FINAL RESULTS: HIGHLY SUCCESSFUL RETREATMENT OF GT1-INFECTED PATIENTS WITH 12 WEEKS OF ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN AFTER FAILURE OF SHORT-DURATION ALL-ORAL THERAPY - (04/29/16)   C-EDGE CO-STAR: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons Who Inject Drugs Receiving Opioid Agonist Therapy - (04/28/16)   C-EDGE CO-STAR: Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - (04/28/16)   An Integrated Safety and Efficacy Analysis of Sofosbuvir-Based Regimens in Patients With Hereditary Bleeding Disorders - (04/28/16)   C-EDGE IBLD: Efficacy and Safety of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C Virus Infection and Inherited Blood Disorders - (04/28/16)   The Additional Impact of Chronic Kidney Disease on Cardiovascular Outcomes and Death Among HCV Patients - (04/28/16)   BASELINE CLINICAL AND LABORATORY PARAMETERS ASSOCIATED WITH CLINICAL BENEFITS OF SUCCESSFUL HCVTREATMENT WITH SOFOSBUVIR/VELPATASVIR IN DECOMPENSATED CIRRHOTIC PATIENTS - (04/27/16)   LEDIPASVIR/SOFOSBUVIR+/-RIBAVIRIN IN HCV POST-TRANSPLANT PATIENTS: REAL-WORLD HETEROGENEOUS POPULATION FROM THE TRIO NETWORK - (04/27/16)   HCV ERADICATION RESULTS IN REDUCTION OF HEPATIC VENOUS PRESSURE GRADIENT 48 WEEKS AFTER END OF TREATMENT; FINAL RESULTS OF THE STUDY OF SOFOSBUVIR PLUS RIBAVIRIN IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION - (04/27/16)   Cost-Effectiveness of Elbasvir (EBR, MK-8742)/Grazoprevir (GZR, MK-5172) Use in Treatment-Naïve and Treatment-Experienced Patients with Hepatitis C Virus (HCV) Genotype 1 Infection and Chronic Kidney Disease (CKD) in the Unites States - (04/27/16)   CHARACTERISTICS AND PREVALENCE OF CHRONIC KIDNEY DISEASE AMONG PATIENTS WITH HEPATITIS C WHO ARE TREATED WITH INTERFERON-FREE DIRECT-ACTING ANTIVIRAL REGIMENS - (04/27/16)   ANALYSIS OF THE IMPACT OF HIV CO-INFECTION ON HEPATITIS C TREATMENT EFFECTIVENESS FOR PATIENTS USING NEW DIRECT-ACTING ANTIVIRALS - (04/27/16)   ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF DIRECT ACTING ANTIVIRAL TREATMENTS FOR HEPATITIS C IN A LARGE POPULATION - (04/27/16)   EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/LEDIPASVIR TREATMENT FOR MONOINFECTED GENOTYPE 1 HCV PATIENTS IN REAL-LIFE CLINICAL PRACTICE: RESULTS FROM SPANISH HEPA-C COHORT - (04/27/16)   High sustained virological response rates using generic direct antiviral treatment for Hepatitis C REDEMPTION-1 - (04/27/16)   The Effect of Sustained Virologic Response on Cerebral Metabolism and Neurocognition in Patients With Chronic Genotype 1 HCV Infection - (04/27/16)   NVR 3-778, a First-in-class HBV Core Inhibitor, Alone and in Combination with Pegylated-interferon (peg-IFN alpha-2a), in Treatment-naïve HBeAg-positive Patients: Early Reductions in HBV DNA and HBeAg - (04/27/16)   (NVR 3-778) Potential first-in-class treatment is well-tolerated in patients with chronic hepatitis B - EASL press release - (04/26/16)   NVR 3-778, a First-in-class HBV Core Inhibitor, Alone and in Combination with Pegylated-interferon (peg-IFN alpha-2a), in Treatment-naïve HBeAg-positive Patients: Early Reductions in HBV DNA and HBeAg - (04/26/16)   A Phase 3 Study of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Week 48 Efficacy and Safety Results - (04/26/16)   PRECLINICAL CHARACTERIZATION OF POTENT CORE PROTEIN ASSEMBLY MODULATORS FOR THE TREATMENT OF CHRONIC HEPATITIS B - (04/26/16)   DIFFERENTIAL REDUCTIONS IN VIRAL ANTIGENS EXPRESSED FROM CCCDNA VS INTEGRATED DNA IN TREATMENT NAïVE HBEAG POSITIVE AND NEGATIVE PATIENTS WITH CHRONIC HBV AFTER RNA INTERFERENCE THERAPY WITH ARC-520 - (04/26/16)   TREATMENT OF CHRONICALLY HBV-INFECTED CHIMPANZEES WITH RNA INTERFERENCE THERAPEUTIC ARC-520 LED TO POTENT REDUCTION OF VIRAL MRNA, DNA AND PROTEINS WITHOUT OBSERVED DRUG RESISTANCE - (04/26/16)   PREDICTING HBSAG CLEARANCE RESPONSES DURING ARC-520 RNA INTERFERENCE (RNAI) THERAPY BASED ON HBSAG EPITOPE PROFILE ANALYSIS - (04/26/16)   The Effect of Sustained Virologic Response on Cerebral Metabolism and Neurocognition in Patients With Chronic Genotype 1 HCV Infection - (04/26/16)   On-Treatment HCV RNA as a Predictor of SVR12 in Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies - (04/26/16)   Sofosbuvir/Velpatasvir for 12 Weeks in HCV-Infected Patients Previously Treated With Placebo: Results of the Deferred Treatment Study - (04/26/16)   Development of Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct Acting Antivirals - (04/25/16)   Baseline Clinical and Laboratory Parameters Associated With Clinical Benefits of Successful HCV Treatment With Sofosbuvir/Velpatasvir in Decompensated Cirrhotic Patients - (04/25/16)   TREATMENT OF HEPATITIS C VIRUS IN PATIENTS WITH ADVANCED CIRRHOSIS: ALWAYS JUSTIFIED? ANALYSIS OF THE HEPA-C REGISTRY - (04/25/16)   INTERFERON (INF)-FREE ANTIVIRAL THERAPY IN CIRRHOTIC PATIENTS INFECTED WITH HEPATITIS C ON THE WAITING LIST FOR LIVER TRANSPLANTATION. EFFICACY AND IMPACT ON DELISTING AND LIVER FUNCTION - (04/25/16)   Clinical outcomes in HCV-infected patients treated with direct acting antivirals - 18-month post-treatment follow-up in the French ANRS CO22 HEPATHER Cohort study. - (04/25/16)   Safety and Efficacy of DAAs in 2432 HCV Patients with advanced Fibrosis: An interim analysis of the Lombardia Regional Network for Viral Hepatitis - (04/25/16)   UK EAP - Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir/ daclatasvir, with or without ribavirin - outcomes compared to untreated patients and long term outcomes....... ANTIVIRAL TREATMENT IN PATIENTS WITH ADVANCED HCV CIRRHOSIS USING SOFOSBUVIR AND LEDIPASVIR/ DACLATASVIR WITH OR WITHOUT RIBAVIRIN - 6 AND 12 MONTH OUTCOMES COMPARED TO UNTREATED PATIENTS - (04/22/16)   Short-Duration Treatment With Sofosbuvir/Velpatasvir Plus GS-9857 in Treatment-Naïve Genotype 1-6 HCV-Infected Patients With or Without Cirrhosis - (04/22/16)   High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and -2 Studies - (04/22/16)   High SVR Rates in Patients With Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I) - (04/22/16)   Ombitasvir/Paritaprevir/Ritonavir With Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egypti an Adults With Chronic HCV Genotype 4 Infection (AGATE-II) - (04/22/16)   High SVR Rates in Patients With Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I) - (04/22/16)   Impact of direct anti-viral agents on inactivation/de-listing of liver transplant candidates listed for decompensated C cirrhosis: a European study - (04/22/16)   The Tolerability of Sofosbuvir/Velpatasvir for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis - (04/22/16)   Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness - (04/22/16)   On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome During Therapy With Ledipasvir/Sofosbuvir With or Without Ribavirin in the Phase 3 ION-1 Study - (04/22/16)   Sofosbuvir/Velpatasvir for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy - (04/22/16)   Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-infected with HCV and HIV: Real-world Heterogeneous Population from the TRIO Network - (04/21/16)   FINAL RESULTS OF THE PYRAMID 1 STUDY, A PHASE 3 REGISTRATIONAL TRIAL OF RAVIDASVIR (PPI-668) AND SOFOSBUVIR IN HCV GENOTYPE-4 PATIENTS: HIGH RATES OF SUSTAINED VIRAL CLEARANCE IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS - (04/21/16)   No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir(LDV/SOF): Real-World Data from 2034 Genotype 1 Patients in the TRIO Network - (04/21/16)   Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis - (04/21/16)   Real World Effectiveness of Ledipasvir/Sofosbuvir in Treatment-Experienced Cirrhotic Genotype 1 Patients with Chronic HCV: A Comparative Analysis of Gilead Sponsored Trials with 4 Real-World Cohorts - (04/21/16)   Real-World Data on the Use of Ribavirin With Ombitasvir/Paritaprevir/r With or Without Dasabuvir in HCV Genotype 1- or 4-Infected Pati ents From the German Hepatitis C Registry - (04/21/16)   Sofosbuvir/Velpatasvir+GS9857 & Sofosbuvir/Velpatasvir Retreatment / Resistance - (04/21/16)   Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)   Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentre Treatment Protocol - (04/21/16)   Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate Use Programme - (04/20/16)   All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: An Analysis of ALLY-3 and ALLY-3+ - (04/20/16)   Daclatasvir Plus Sofosbuvir With or Without Ribavirin for Treatment of Chronic HCV Infection in Patients With Advanced Liver Disease: Results of a European Compassionate Use Programme - (04/20/16)   High Sustained Virologic Response Rates in Patients Infected With HCV genotype 2 With Baseline NS5A Polymorphisms Treated With Daclatasvir-Based Regimens - (04/20/16)   Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Infection in Patients With Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Programme - (04/20/16)   Next-Generation Sequencing Analysis of NS5A and NS5B Minor Resistance-Associated Variants in Patients with HCV Genotype 3 Infection who Failed Treatment with Daclatasvir Plus Sofosbuvir - (04/20/16)   Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis - (04/20/16)   INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION ....MSM & IDUs, HIV+ - (04/20/16)   Evidence of impressive real world SVR from the Portuguese ledipasvir/sofosbuvir and sofosbuvir universal coverage program to erradicate (eliminate) hepatitis C - (04/19/16)   Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected With Chronic HCV Who Have Advanced Liver Disease Or Are Post Liver Transplant (SOLAR-1 and -2 Studies) - (04/19/16)   High Rate of SVR in Adolescents Treated With the Combination of Ledipasvir/Sofosbuvir - (04/19/16)   100% SVR12 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITH CIRRHOSIS - (04/19/16)   Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients With Chronic Genotype 1 or 4 HCV Infection - (04/19/16)   High Efficacy of an 8-Week, 3-Drug Regimen of MK-3682/Grazoprevir/MK-8408 in HCV Genotype 1, 2, or 3-Infected Patients: SVR24 Data from the Phase 2 C-CREST 1 and 2 Studies - (04/19/16)   Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients With Chronic Genotype 1 or 4 HCV Infection - (04/18/16)   High Efficacy and Favourable Safety of ABT-493 + ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients With Cirrhosis (SURVEYOR-I) - (04/18/16)   100% SVR4 and Favorable Safety of ABT-493 + ABT-530 Administered for 12 Weeks in Non-Cirrhotic Patients With Genotypes 4, 5, or 6 Infection (SURVEYOR-I) - (04/18/16)   Safety of ABT-493 + ABT-530 Co-Administered in Patients With HCV Genotype 1-6 Infection: Results From the SURVEYOR-I and SURVEYOR-II Studies - (04/18/16)   High SVR Rates With the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients With HCV Genotype 1 or 2 Infection - (04/18/16)   Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (04/18/16)   Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies - (04/18/16)   HIGH SVR RATES WITH ABT-493 + ABT-530 CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION - (04/18/16)   AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals - (04/18/16)   Gilead Presents New Data Highlighting Progress in Liver Fibrosis (NASH, primary sclerosing cholangitis) - (04/18/16)   AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6 - (04/18/16)   Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™ - (04/18/16)   In a 5-day Monotherapy Trial, MK-8408 Demonstrated Potent Antiviral Activity and Improved Resistance Profile in HCV Patients With Genotypes 1, 2, and 3 Infections - (04/18/16)   PAN-GENOTYPIC EVALUATION OF AL-335, A CLINICAL STAGE URIDINE ANALOG INHIBITOR OF HEPATITIS C VIRUS POLYMERASE - (04/18/16)   AL-335, A ONCE-DAILY PANGENOTYPIC NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY OVER 7 DAYS IN TREATMENT-NAÏVE GENOTYPE 1-4 PATIENTS - (04/18/16)   Effect of Baseline Resistance-Associated Variants on SVR With the 3D Regimen Plus RBV - (04/18/16)   Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection - (04/15/16)   A Phase 3 Study of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in Patients With HBeAg-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results - (04/15/16)   REAL-WORLD SAFETY AND EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/R ± DASABUVIR ± RIBAVIRIN IN THE GERMAN HEPATITIS C REGISTRY (clear version) - (04/15/16)   Long-Term Follow-up of Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antiviral Regimens: Maintenance of SVR, Persistence of Resistance Mutations, and Clinical Outcomes - (04/15/16)   Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated With Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks - (04/15/16)   The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (3D±R): a large multi-center cohort - (04/15/16)   Resistance Analysis in 1284 Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir in the Phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 Studies - (04/15/16)   RG-101 IN COMBINATION WITH 4 WEEKS OF ORAL DIRECT ACTING ANTIVIRAL THERAPY ACHIEVES HIGH VIROLOGIC RESPONSE RATES IN TREATMENT NAïVE GENOTYPE 1 AND 4 CHRONIC HEPATITIS C PATIENTS: INTERIM RESULTS FROM A RANDOMISED, MULTI-CENTER, PHASE 2 STUDY - (04/15/16)   HIGH EFFICACY OF ABT-493 AND ABT-530 IN HCV GENOTYPE 1-INFECTED PATIENTS WHO HAVE FAILED DIRECT-ACTING ANTIVIRAL-CONTAINING REGIMENS: THE MAGELLAN-I STUDY - (04/15/16)   Hepatitis C virus reinfection incidence and outcomes among HIV-positive MSM in Western Europe - (04/15/16)   Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study - (04/15/16)   High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated With Direct-Acting Antivirals - (04/15/16)   C-EDGE: HEAD 2 HEAD - Efficacy and Safety of Elbasvir/Grazoprevir versus Sofosbuvir /Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and Prior PR Treatment Failure Subjects with Chronic HCV GT1 or 4 Infection - (04/15/16)   High Efficacy of Sofosbuvir/Velpatasvir/GS-9857 With or Without Ribavirin for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1 HCV Infection - (04/15/16)   AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients - (04/14/16)   Merck's ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial - (04/14/16)   Pre-EASL Notes from Jules - (04/14/16)   Arbutus to Present Preclinical HBV Data at EASL 2016 - (04/07/16)   Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016 - (04/07/16)   AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016 - new HCV Drug Pipeline ABT493+ABT530 - (04/07/16)   Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL) - (04/07/16)